Shenxiong Huanglian Jiedu Formula in the treatment of mild to moderate Alzheimer's disease:a randomized controlled trial

Wangjing Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2024年7月23日

适应症

试验速览

暂无简介。

•1) It conforms to the diagnostic standard of western medicine (refer to the core clinical standard of AD dementia formulated by NIA-AA in 2011) and the syndrome differentiation standard of traditional Chinese medicine; 2) Patients with mild to moderate AD: the total score of mini-mental state examination(MMSE) is 10-26; Clinical Dementia Rating(CDR) score is 1-2; 3) Age =60 years and =85 years; 4) The course of disease is =6 months; 5) The subjects can complete neuropsycholosgical test ; 6) The subjects have stable caregivers; 7) Patients and their legal guardians agree to participate in the experiment and sign the informed consent form.

•1) Dementia caused by other reasons, such as vascular dementia, Lewy body dementia, frontotemporal dementia, brain tumor, hydrocephalus, alcoholism, etc. 2) Patients with serious circulatory system, respiratory system, digestive system and other diseases; 3) Severe liver and kidney dysfunction; 4) Patients tak drugs that affect cognitive function except research drugs within one month; 5) Patients are allergic or known to be allergic to the drug ingredients in the study.

发起方

Wangjing Hospital, China Academy of Chinese Medical Sciences